Thailand Shifts from Buying Medicines to Co-Developing and Co-Producing Them

The Ministry of Public Health in Thailand has successfully concluded negotiations with two of the world's largest pharmaceutical companies, MSD and Roche, with Sandoz and over a dozen more global drugmakers slated for future talks. This marks a significant turning point in the country's economic strategy, aiming to elevate Thailand beyond contract manufacturing into co-developing and co-producing high-technology, high-value products. According to Government Spokesperson Dr. Ekkapob Pianpises, Roche has indicated an initial investment of THB15 billion (approximately US$453 million) in pharmaceutical R&D in Thailand. With ongoing negotiations with other companies, total research funding could potentially reach THB100 billion (approximately US$3 billion). The discussions also encompass the establishment of pharmaceutical manufacturing bases on Thai soil. This initiative promises lower-priced access to new medicines for hard-to-treat diseases through Thailand’s universal health coverage system. By participating in drug development, Thailand gains not only the science and jobs but also a stronger position in price negotiations. For Thai patients, this means earlier access to breakthrough treatments, and for Thai scientists, clinical researchers, and manufacturing talent, it opens up new career pipelines at home. This aligns with Thailand's broader ambition to become a Medical Investment Hub in Southeast Asia, a tangible deliverable that fosters economic growth while enhancing quality of life. Thailand is positioning itself not just as a destination for business, but for discovery.